Clinical Trial

Effect of Mycobacterial Infection on Immune Status

Study acronym: EMIIS
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 10, 2026 (before its estimated July 20, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study, titled "Effect of Mycobacterial Infection on Immune Status" (EMIIS), investigates the immune-driven mechanisms of mycobacterial infections, focusing on the dynamic immune characteristics of multidrug-resistant tuberculosis (MDR-TB), nontuberculous mycobacterial (NTM) infections, and tuberculous pleurisy. Mycobacterial infections (including the Mycobacterium tuberculosis complex and nontuberculous mycobacteria) remain a major global public health threat. EMIIS is a single-center, randomized, single-blind,prospective study. The study recruited 120 participants, divided into groups of healthy individuals/community-acquired pneumonia patients, active pulmonary tuberculosis patients, latent tuberculosis infection patients, tuberculous pleurisy patients, and nontuberculous mycobacteria patients. Blood samples were collected from all groups within 3 days before treatment and 2-3 months after treatment. Pleural effusion samples were additionally collected from the tuberculous pleurisy group within 3 days before treatment and 2 months after treatment. Exhaled breath condensate (EBC) was collected from the nontuberculous mycobacteria group. Utilizing mass cytometry (CyTOF) and multi-dimensional indicators, the study aims to elucidate the immune-driven mechanisms of mycobacterial infections and provide new strategies for individualized treatment.
Trial Details
NCT Number NCT07638670
Lead Sponsor First Affiliated Hospital of Ningbo University
Conditions Tuberculosis
Enrollment 120 participants
Start Date 2025-07-09
Primary Completion 2026-07-20 (estimated)
Study Completion 2026-07-20 (estimated)
Updated on ClinicalTrials.gov 2026-06-10